1. Home
  2. NVRI vs HROW Comparison

NVRI vs HROW Comparison

Compare NVRI & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enviri Corporation

NVRI

Enviri Corporation

HOLD

Current Price

$20.31

Market Cap

1.6B

Sector

Miscellaneous

ML Signal

HOLD

HROW

Harrow Inc.

HOLD

Current Price

$42.06

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVRI
HROW
Founded
1853
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2026
2008

Fundamental Metrics

Financial Performance
Metric
NVRI
HROW
Price
$20.31
$42.06
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$69.86
AVG Volume (30 Days)
345.9K
535.8K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
71.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.87
$31.62
Revenue Next Year
$3.70
$50.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.56
$28.54
52 Week High
$24.20
$54.98

Technical Indicators

Market Signals
Indicator
NVRI
HROW
Relative Strength Index (RSI) 42.21 58.04
Support Level $19.71 $40.65
Resistance Level $21.42 $44.50
Average True Range (ATR) 1.23 1.93
MACD -0.21 0.25
Stochastic Oscillator 19.42 84.36

Price Performance

Historical Comparison
NVRI
HROW

About NVRI Enviri Corporation

Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: